Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Abstract

Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor. (Funded by Astellas Pharma US and Seagen; EV-301 ClinicalTrials.gov number, NCT03474107.).

Keywords

Affiliated Institutions

• Smilow Cancer Hospital US
• University of Ulsan KR
• Seagen (United States) US
• Harvard University US
• University of Antwerp BE
• Institut Gustave Roussy FR
• Queen Mary University of London GB
• Ulsan College KR
• Dana-Farber Cancer Institute US
• National Cancer Center Hospital East JP
• Université Paris-Saclay FR
• Hospital Universitario 12 De Octubre ES
• Memorial Sloan Kettering Cancer Center US
• Instituto de Investigación Marqués de Valdecilla ES
• Astellas Pharma (United States) US
• Asan Medical Center KR

Related Publications